When it Takes a Warning Letter to Spur Company Action
[Editor's Note: Part II appeared in the February 2019 issue.]
In the not-too-distant past, I was driving
to downtown Washington, D.C. on a
rainy morning in September. After fighting
the tortuous traffic, I finally arrived at
the PDA/FDA Joint Regulatory Conference.
My first order of business? Find that life-sustaining
cup of coffee. After checking
in, I made a beeline to the coffee stand.